Evidence map›Paper›PMID 36420169›Full record

ArticleComputational and structural biotechnology journal2022

Extending Janus lectins architecture: Characterization and application to protocells.

Simona Notova, Lina Siukstaite, Francesca Rosato, Federica Vena, Aymeric Audfray, Nicolai Bovin, Ludovic Landemarre, Winfried Römer, Anne Imberty

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Simona NotovaUniversité Grenoble Alpes, CNRS, CERMAV, 38000 Grenoble, France.
Lina SiukstaiteFaculty of Biology, University of Freiburg, 79104 Freiburg, Germany.
Francesca RosatoFaculty of Biology, University of Freiburg, 79104 Freiburg, Germany.
Federica VenaGLYcoDiag, 2 rue du Cristal, 45100 Orléans, France.
Aymeric AudfrayMalvern Panalytical SAS, 30 rue du docteur Levy, 69200 Vénissieux, France.
Nicolai BovinShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow 117997, Russian Federation.
Ludovic LandemarreGLYcoDiag, 2 rue du Cristal, 45100 Orléans, France.
Winfried RömerFaculty of Biology, University of Freiburg, 79104 Freiburg, Germany.
Anne ImbertyUniversité Grenoble Alpes, CNRS, CERMAV, 38000 Grenoble, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synthetic biology is a rapidly growing field with applications in biotechnology and biomedicine. Through various approaches, remarkable achievements, such as cell and tissue engineering, have been already accomplished. In synthetic glycobiology, the engineering of glycan binding proteins is being exploited for producing tools with precise topology and specificity. We developed the concept of engineered chimeric lectins, i.e., Janus lectin, with increased valency, and additional specificity. The novel engineered lectin, assembled as a fusion protein between the β-propeller domain from

Indexed as

Carbohydrate-binding proteinGalili epitopeLectinsProtein engineeringSynthetic biology

Identifiers

PMID36420169
PMCPMC9668655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.